Health Care [ 3/12 ] | Biotechnology [ 13/73 ]
NASDAQ | Common Stock
Metsera, Inc., a clinical-stage biotechnology company, develops injectable and oral nutrient stimulated hormone analog peptides to treat obesity, overweight, and related diseases.
It develops MET-097i and MET-233i for the treatment of obesity and overweight; MET-233i/MET-097i; and MET-002, MET-224o, MET-067i, and MET-034i to treat disorders, such as diabetes and obesity, as well as MET-815i to reduce weight or prevents weight gain.
The company was incorporated in 2022 and is based in New York, New York.
As of November 13, 2025, Metsera, Inc. operates as a subsidiary of Pfizer Inc.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Sep 30, 25 | -1.11 | -0.68 Decreased by -64.44% |
| Jul 29, 25 | -0.66 | -0.68 Increased by +2.22% |
| May 12, 25 | -1.03 | -1.04 Increased by +0.96% |
| Mar 26, 25 | -3.52 | -0.80 Decreased by -340.00% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 25 | 0.00 Decreased by N/A% | -116.23 M Decreased by -6.00% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 25 | 0.00 Decreased by N/A% | -68.72 M Decreased by -157.09% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 25 | 0.00 Decreased by N/A% | -76.59 M Decreased by -285.25% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 24 | 0.00 Decreased by N/A% | -52.87 M Decreased by -345.38% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 24 | 0.00 - | -109.65 M - | Decreased by N/A% - |
| Jun 30, 24 | 0.00 - | -26.73 M - | Decreased by N/A% - |
| Mar 31, 24 | 0.00 - | -19.88 M - | Decreased by N/A% - |
| Dec 31, 23 | 0.00 - | -11.87 M - | Decreased by N/A% - |